Basiliximab

Basiliximab is a recombinant chimeric monoclonal antibody belonging to the interleukin-2 receptor antagonist class of immunosuppressive medicines. It selectively binds to the alpha chain of the high-affinity interleukin-2 receptor, also known as CD25, which is expressed on activated T lymphocytes. By blocking interleukin-2 from binding to this receptor, basiliximab inhibits activation and proliferation of T cells involved in the immune response against a transplanted organ. It is primarily used as induction therapy to reduce the risk of acute rejection in patients receiving a new kidney transplant. Basiliximab is administered intravenously and is given as part of a broader immunosuppressive regimen that commonly includes a calcineurin inhibitor and corticosteroids, with other medicines such as mycophenolate mofetil or azathioprine used according to the transplant protocol. In adults, the standard regimen consists of two 20 mg doses, with the first dose administered shortly before transplantation and the second dose several days after transplantation when appropriate. Pediatric dosing is weight-based. Because basiliximab is administered during a period of intensive immunosuppression, patients require monitoring for hypersensitivity reactions, infections, blood-count abnormalities and complications associated with the overall transplant immunosuppressive regimen.

Basiliximab was developed as a chimeric monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, providing selective inhibition of activated T-cell proliferation during the early period following transplantation. The U.S. Food and Drug Administration approved Simulect on 12 May 1998 for prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen containing modified cyclosporine and corticosteroids. The European Commission granted marketing authorisation for Simulect on 9 October 1998. European authorization covers prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adults and pediatric patients from one year of age, in combination with specified immunosuppressive regimens. Indian regulatory records and marketed-product information document basiliximab injection for use as induction therapy in kidney transplantation. Early phase III clinical studies evaluated basiliximab against placebo in primary kidney transplant recipients receiving background immunosuppression and demonstrated a reduction in acute cellular rejection during the early post-transplant period. Subsequent studies evaluated basiliximab in adults and children and established weight-based pediatric dosing and its use with different maintenance immunosuppressive combinations.

Basiliximab is used for prophylaxis of acute organ rejection in patients undergoing de novo allogeneic kidney transplantation. In adults, it is administered as part of an immunosuppressive regimen that generally includes a calcineurin inhibitor and corticosteroids, with additional medicines such as azathioprine or mycophenolate mofetil used according to the transplant protocol. European authorization includes adult and pediatric patients aged one year and older undergoing kidney transplantation. Basiliximab is intended as induction therapy around the time of transplantation rather than as long-term maintenance immunosuppression. Its use in other solid-organ transplant settings has not been established as an approved indication in the current U.S. prescribing information. Treatment should only be initiated by healthcare professionals experienced in transplantation and immunosuppressive therapy, and basiliximab should be administered only when transplantation and the accompanying maintenance immunosuppressive regimen are expected to proceed.

Basiliximab is administered intravenously either as a slow injection or as an infusion according to the product instructions and institutional transplant protocol. In adults, the standard regimen is two 20 mg doses. The first dose is administered within two hours before transplantation surgery, and the second dose is administered approximately four days after transplantation. The second dose should be withheld when severe hypersensitivity occurs or when complications such as graft loss make continued administration inappropriate. In pediatric patients weighing less than 35 kg, the recommended regimen is two 10 mg doses, while patients weighing 35 kg or more generally receive the adult two-dose 20 mg regimen. Basiliximab is used together with other immunosuppressive medicines and does not replace maintenance therapy. Because the medicine is intended for induction around transplantation, dosing is closely coordinated with the surgical and transplant schedule. Administration should occur under qualified medical supervision with appropriate facilities available to manage hypersensitivity or other acute complications.

Common adverse effects reported with basiliximab in clinical studies include constipation, urinary tract infection, pain, nausea, peripheral edema, hypertension, anemia, headache, elevated potassium levels, increased cholesterol, surgical wound complications, increased serum creatinine, low phosphate levels, diarrhea and upper respiratory tract infections. In pediatric transplant recipients, reported adverse effects can include urinary tract infections, fever, upper respiratory or viral infections, hypertension and constipation. Because basiliximab is administered together with other immunosuppressive medicines, many adverse effects observed after transplantation may also be related to the accompanying immunosuppressive regimen, surgery or the underlying clinical condition. The frequency and severity of adverse effects vary according to age, transplant status, concomitant medicines and individual patient factors. Clinical monitoring remains important throughout the early post-transplant period.

The most important serious safety concern associated with basiliximab is severe acute hypersensitivity, including anaphylactoid or anaphylactic-type reactions. Reactions can occur during initial exposure or, in some circumstances, after re-exposure and may include rash, urticaria, wheezing, bronchospasm, low blood pressure, rapid heart rate, breathing difficulty, pulmonary edema or other severe manifestations. If a severe hypersensitivity reaction occurs, basiliximab should be permanently discontinued and no further dose administered. The risk of serious infection and malignancy must also be considered in the context of the overall immunosuppressive regimen used after transplantation. Basiliximab itself is a targeted immunosuppressant, but patients remain exposed to substantial immunosuppressive effects from concomitant medicines. Patients who receive basiliximab and subsequently experience premature discontinuation of their accompanying immunosuppression may be at particular risk of hypersensitivity on later re-exposure. Pregnancy and breastfeeding require specific assessment because available product information does not support routine use during these periods.

Before administration, healthcare professionals should confirm that kidney transplantation is proceeding and that the patient will receive an appropriate accompanying immunosuppressive regimen. A history of previous basiliximab exposure and hypersensitivity should be reviewed carefully because severe reactions can occur with re-exposure. Baseline assessment should include infection status, blood counts, renal and hepatic function and relevant cardiovascular or allergic history, together with the routine pre-transplant evaluation. Basiliximab does not undergo conventional hepatic CYP metabolism and therefore has fewer classic metabolic drug interactions than many oral medicines. However, its use with other immunosuppressive agents produces additive effects on immune function, and the complete transplant medication regimen must be monitored for infection, hematologic, renal and other toxicities. Vaccination status should be reviewed as part of transplant planning because immune responses can be reduced by the overall immunosuppressive regimen. Patients should be monitored closely during and after administration for hypersensitivity and for complications associated with transplantation and concomitant immunosuppression.

Basiliximab should be prescribed and administered only by teams experienced in organ transplantation and immunosuppressive therapy. Before the first dose, pharmacists and transplant clinicians should verify the transplant schedule, patient weight where pediatric dosing applies, formulation strength, concomitant immunosuppressive medicines and history of previous basiliximab exposure. The first dose should be coordinated closely with the transplant procedure, while the second dose should be given only when clinically appropriate after transplantation. Patients and caregivers should be counselled to report rash, swelling, wheezing, breathing difficulty, dizziness or other symptoms suggestive of hypersensitivity immediately. The transplant team should maintain appropriate infection surveillance and routine laboratory monitoring because basiliximab is used within a broader immunosuppressive strategy. Special attention should be given to re-exposure after previous treatment, particularly when prior immunosuppression was interrupted or a previous graft was lost. Coordination between transplant surgeons, nephrologists, pharmacists, nurses and laboratory teams supports safe administration and appropriate monitoring.